1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 16 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2016Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trialZdenkowski, N.; Forbes, J.F.; Boyle, F.M.; Kannourakis, G.; Gill, P.G.; Bayliss, E.; Saunders, C.; Della-Fiorentina, S.; Kling, N.; Campbell, I.; Mann, G.B.; Coates, A.S.; Gebski, V.; Davies, L.; Thornton, R.; Reaby, L.; Cuzick, J.; Green, M.
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2014Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsYeung, D.; Mauro, M.
2015Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non–small-cell lung cancerRamalingam, S.S.; Shtivelband, M.; Soo, R.A.; Barrios, C.H.; Makhson, A.; Segalla, J.G.; Pittman, K.B.; Kolman, P.; Pereira, J.R.; Srkalovic, G.; Belani, C.P.; Axelrod, R.; Owonikoko, T.K.; Qin, Q.; Qian, J.; McKeegan, E.M.; Devanarayan, V.; McKee, M.D.; Ricker, J.L.; Carlson, D.M.; et al.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2013Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomesCho, Y.; Badve, S.; Hawley, C.; McDonald, S.; Brown, F.; Boudville, N.; Bannister, K.; Clayton, P.; Johnson, D.
2013Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialVermorken, J.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; SkladowskI, K.; Tahara, M.; Pai, V.; Faivre, S.; Blajman, C.; Forastiere, A.; Stein, B.; Oliner, K.; Pan, Z.; Bach, B.
2015A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinomaPal, S.; Azad, A.; Bhatia, S.; Drabkin, H.; Costello, B.; Sarantopoulos, J.; Kanesvaran, R.; Lauer, R.; Starodub, A.; Hauke, R.; Sweeney, C.; Hahn, N.; Sonpavde, G.; Richey, S.; Breen, T.; Kremmidiotis, G.; Leske, A.; Doolin, E.; Bibby, D.; Simpson, J.; et al.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2011Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialKantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.

Discover